Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY)

Historical Holders from Q3 2020 to Q3 2025

Type / Class
Equity / Common stock, par value $0.0001 per share
Symbol
INZY
Shares outstanding
64,521,093
Price per share
$4.00
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
0
Total reported value
$0
Share change
-50,560,856
Value change
-$202,243,836
Number of holders
0
Price from insider filings
$4.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GLAZER CAPITAL, LLC 6.6% $17,007,760 4,251,940 Glazer Capital, LLC 28 May 2025
BlackRock, Inc. 4.1% $3,143,140 2,663,678 BlackRock, Inc. 30 Jun 2025
EVENTIDE ASSET MANAGEMENT, LLC 3.5% $1,820,400 2,220,000 Eventide Asset Management, LLC 31 Dec 2024
Affinity Asset Advisors, LLC 2.9% $2,203,898 1,867,710 Affinity Healthcare Fund, LP 20 May 2025
As of 30 Sep 2025, Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) has 0 institutional shareholders filing 13F forms. They reported no common stock holdings, but disclosed options positions.

Institutional Holders of Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 0 $0 -$202,243,836 $4.00 0
2025 Q2 50,562,361 $202,249,948 +$62,663,407 $4.00 86
2025 Q1 46,721,833 $42,515,835 -$10,880,579 $0.91 97
2024 Q4 52,395,972 $145,138,175 -$16,307,259 $2.77 103
2024 Q3 54,589,806 $285,504,785 +$3,379,518 $5.23 88
2024 Q2 53,828,193 $240,074,432 +$12,985,182 $4.46 89
2024 Q1 49,873,972 $382,034,519 +$1,437,709 $7.66 87
2023 Q4 57,917 $246,727 +$64,339 $4.26 2
2023 Q3 48,693,887 $204,515,110 +$58,070,356 $4.20 77
2023 Q2 34,130,027 $190,100,693 +$11,986,649 $5.57 72
2023 Q1 31,956,218 $183,104,839 +$30,199,265 $5.73 49
2022 Q4 28,942,741 $30,390,733 -$8,198,090 $1.05 35
2022 Q3 30,838,062 $82,660,000 -$2,246,220 $2.68 36
2022 Q2 31,507,937 $149,159,000 +$68,476,235 $4.77 38
2022 Q1 17,401,036 $71,154,000 -$1,906,448 $4.09 47
2021 Q4 17,310,088 $118,019,000 -$3,801,446 $6.82 48
2021 Q3 17,467,195 $202,450,000 -$48,737,003 $11.59 48
2021 Q2 19,782,863 $337,102,000 +$9,949,669 $17.04 50
2021 Q1 19,164,436 $379,445,000 +$15,464,812 $19.80 55
2020 Q4 18,360,151 $378,973,000 +$7,774,422 $20.64 53
2020 Q3 16,305,719 $428,665,000 +$428,665,001 $26.29 52